Method of treating heart failure with preserved ejection fraction with probenecid
Described herein are inventions directed to methods of treating a diastolic cardiac dysfunction and the symptoms thereof in a subject that includes administering an amount of a TRPV2 receptor agonist effective to treat the diastolic cardiac dysfunction. The TRPV2 receptor agonist may be administered in at least one of an injection, orally, or transdermally. The amount of TRPV2 receptor agonist is sufficient to result in an improved performance on quantitative diagnostic criteria. In an embodiment, the TRPV2 receptor agonist is administered over a period of about 8 hours to about 24 hours. The TRPV2 receptor agonist may be used for short term treatments, i.e., less than a week, or it may be administered in a long term manner, i.e., over a period of weeks, months, or even years. Exemplary TRPV2 receptor agonists include probenecid, 2-aminoethoxydiphenyl borate, cannabinol, cannabidiol, and combinations thereof.
1. A method of treating heart failure with preserved ejection fraction (HFpEF) in a subject comprising intravenously infusing an amount of probenecid to achieve a plasma concentration effective to treat the cardiac dysfunction heart failure with preserved ejection fraction in the subject.
2. The method of claim 1 wherein the amount of probenecid is sufficient to result in an improved performance on a standardized 6 minute walk test, an improved New York Heart Association (NYHA) classification, a lower diuretic dose requirement, a lower serum B-type Natriuretic Peptide (BNP) level, a normalization of serum sodium concentration, or combinations thereof.
3. The method of claim 1 using a bolus injection or continuous intravenous infusion.
4. The method of claim 1 wherein a dose of probenecid ranges from about 1 mg/kg/day to about 100 mg/kg/day.
5. The method of claim 1 wherein probenecid is administered over a period of about 24 hours per day.
6. The method of claim 1 wherein the subject is treated with probenecid for at least one week.
7. The method of claim 1 wherein the subject is treated with probenecid for at least one month.
8. A method of treating heart failure with preserved ejection fraction in a subject comprising administering probenecid to the subject in a dosing regimen to maintain a therapeutic plasma concentration to treat the heart failure with preserved ejection fraction in the subject.
9. The method of claim 8 wherein the therapeutic plasma concentration of probenecid is sufficient to result in an improved performance on a standardized 6 minute walk test, an improved NYHA classification, a lower diuretic dose requirement, a lower serum BNP level, a normalization of serum sodium concentrations, or combinations thereof.
10. The method of claim 8 wherein the dosing regimen includes intravenous administration of the dose of probenecid.
11. The method of claim 8 wherein probenecid is administered for at least one week.
12. The method of claim 1 where treating HFpEF includes curing the patient.